Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease?

  • C. Konradi
  • P. Riederer
  • H. Heinsen
Part of the Key Topics in Brain Research book series (KEYTOPICS)


The distribution of monoamine oxidase subtypes in the human brain-stem is described. Results are discussed in relation to the MAO-B inhibiting therapy of Parkinson’s disease (PD). Additionally, attention is focused onto the pathogenesis of PD, especially on radical mechanisms which might be mediated via exotoxins and amplified by endogenous radicals.


Monoamine Oxidase Parkinsonian Patient Radical Hypothesis Endogenous Radical Neurotoxin MPTP 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with “Madopar” and 1-deprenyl in Parkinson’s disease. Lancet i: 439–443CrossRefGoogle Scholar
  2. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of 1-deprenyl to Madopar® treatment in Parkinson’s disease: A long-term study. J Neural Transm 64: 113–127PubMedCrossRefGoogle Scholar
  3. D’Amato RJ, Alexander GM, Schwartzmann RJ, Kitt CA, Price DL, Snyder SH (1987) Neuromelanin: A role in MPTP-induced neurotoxicity. Life Sci 40: 705–712PubMedCrossRefGoogle Scholar
  4. D’Amato RJ, Alexander GM, Schwartzmann RJ, Kitt CA, Price DL, Snyder SH (1987) Neuromelanin: A role in MPTP-induced neurotoxicity. Life Sci 40: 705–712PubMedCrossRefGoogle Scholar
  5. Davis GC, Williams AC, Markey SP, Ebert MH, Calne ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogous. Psychiat Res 1: 249–254CrossRefGoogle Scholar
  6. Heikkila RE, Hess H, Duvoisin RC (1985) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse: Relationships between monoamine oxidase, MPTP metabolism and neurotoxicity. Life Sci 36: 231–236PubMedCrossRefGoogle Scholar
  7. Kinemuchi H, Fowler CJ, Tipton KF (1987) The neurotoxicity of 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson’s disease. Neurochem Int 11 /4: 359–373PubMedCrossRefGoogle Scholar
  8. Kishimoto S, Kimura H, Maeda T (1983) Histochemical demonstration for monoamine oxidase ( MAO) by a new coupled peroxidation method. Cell Mol Biol 29: 61–69PubMedGoogle Scholar
  9. Konradi C, Riederer P, Youdim MBH (1986) Hydrogen peroxide enhances the activity of monoamine oxidase type-B but not of type-A: A pilot study. J Neural Transm [Suppl] 22: 61–73Google Scholar
  10. Perry TL, Godin DV, Hansen S (1982) Parkinson’s disease: A disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305–310PubMedCrossRefGoogle Scholar
  11. Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, Foulks JG, Wall RA (1985) Partial protection from the dopaminergic neurotoxin N-methyl4-phenyl-1, 2, 3, 6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett 60: 109–114PubMedCrossRefGoogle Scholar
  12. Riederer P, Jellinger K, Seemann D (1984) Monoamine oxidase and Parkinsonism. In: Tipton KF, Dostert P, Strolin-Benedetti M (eds) Monoamine oxidase and disease. Academic Press, London, pp 403–415Google Scholar
  13. Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1988) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. ( Submitted )Google Scholar
  14. Singer TP, Salach JI, Castagnoli N, Trevor A (1986) Processing of MPTP to toxic metabolites by monoamine oxidases. In: Markey SP, Castagnoli N, Trevor AJ, Kopin IJ (eds) MPTP: A neurotoxin producing a parkinsonian syndrome. Academic Press, London, pp 235–251Google Scholar
  15. Yong VW, Perry TL, Krisman AA (1986) Depletion of glutathione in brain-stem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci Lett 63: 56–60PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • C. Konradi
    • 1
  • P. Riederer
    • 1
  • H. Heinsen
    • 1
  1. 1.Clinical Neurochemistry and Morphological Brain Research, Department of PsychiatryUniversity of WürzburgFederal Republic of Germany

Personalised recommendations